Skip to main content
Skip to main content
EHC logo

Encompass Health Corporation (EHC) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$121.04 -$0.48 (-0.40%) |Exceptional · 89
Encompass Health Corporation (EHC) bottom line: Strongly Bullish — our Council read (76/100) and AI Score (89/100) broadly agree. Strongest signal: Business Quality · Biggest watch-out: Financial Safety.Educational signal, not a buy or sell recommendation. Compare sector peers → · Read the method →
MCap: $12.0B| P/E Ratio: 16.46| Vol: 671K| Target: $150.25 (+24.1%) (Aug 25, 2026) (estimate, not advice)| 52-wk range: $92.77 – $127.99

P/E 16.46 means the share price is 16.46 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $12.0B is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Encompass Health Corporation (EHC) trades at $121.04 with MoonshotScore 89/100 (Grade A+). Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States. Market cap: $12.0B, Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: May 9, 2026
Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States. The company operates through its Inpatient Rehabilitation and Home Health & Hospice segments, offering specialized care to patients recovering from various conditions.

EHC stock analysis for 2026: Analysts have set a consensus price target of $150.25 for Encompass Health Corporation, suggesting 24.1% upside from the current price of $121.04. The AI MoonshotScore is 89/100, in the Exceptional band (80-100) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the EHC film Every key number, told as a short cinematic story — just press play. ~2 min

These figures come from statements filed 12 months ago — the most recent this company has published.

Council Score · Weighted Average of 3 Disciplines
Strongly Bullish 76/100 · A

EHC: 3/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
MoonshotScore · Five-pillar engine · 89/100
Business Quality
Strong Is this a genuinely good business?
Financial Safety
Neutral Could this blow up on me?
Valuation
Moderate Am I paying a fair price?
Growth Durability
Strong Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?

Strongest side: Business Quality (9/10, Strong). Weakest side: Financial Safety (5/10, Neutral).

Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Neutral read
Simons-style lens (simulated)Jim Simons
Neutral read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Favorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Moderate
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Encompass Health Corporation (EHC) Healthcare & Pipeline Overview

CEOMark J. Tarr
Employees29,699
HeadquartersBirmingham, AL, US
IPO Year1986

Encompass Health Corporation, a major player in the U.S. post-acute healthcare market, delivers facility-based and home-based services through its Inpatient Rehabilitation and Home Health & Hospice segments. With a wide geographic reach and focus on specialized rehabilitative care, EHC addresses the growing demand for post-acute services.

Data Provenance | Financial Data Quantitative Analysis NYSE Analysis: May 9, 2026

What Is the Investment Thesis for EHC?

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

The company's diversified service offerings, spanning inpatient rehabilitation and home health & hospice, cater to a broad range of patient needs. With a market capitalization of $12.0B and a P/E ratio of 16.46, EHC demonstrates financial stability and profitability, supported by a 10.0% profit margin and a 58.8% gross margin. Growth catalysts include the increasing demand for post-acute care driven by an aging population and advancements in medical treatments. The company's strategic expansion of its facility network and home health locations further supports revenue growth. Potential risks include regulatory changes in healthcare reimbursement and increased competition from other post-acute care providers.

Based on FMP financials and quantitative analysis

EHC Key Highlights

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $12.0B, reflecting substantial investor confidence in the company's market position and future growth prospects.

  • P/E ratio of 16.46, indicating a reasonable valuation relative to earnings, suggesting potential for further appreciation.
  • Profit margin of 10.0%, demonstrating efficient operations and effective cost management within the healthcare sector.
  • Gross margin of 58.8%, highlighting the company's ability to generate significant revenue from its services, exceeding industry averages.
  • Dividend yield of 0.70%, providing a steady income stream for investors, enhancing the overall investment appeal.

Who Are EHC's Competitors?

EHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
ALGN Align Technology, Inc. $150.72 -1.44% $10.8B 825-pillar
RDY Dr. Reddy's Laboratories Limited $12.01 +2.52% $10.0B 795-pillar
FMS Fresenius Medical Care AG & Co. KGaA $22.23 -0.45% $11.9B 825-pillar
SOLV Solventum Corporation $87.80 +0.17% $15.2B 595-pillar
ENSG The Ensign Group, Inc. $172.79 +0.60% $10.1B 745-pillar
DVA DaVita Inc. $181.33 -0.92% $11.6B 745-pillar
UHS Universal Health Services, Inc. $172.72 -1.74% $10.5B 935-pillar
THC Tenet Healthcare Corporation $263.46 -2.09% $21.2B 885-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EHC's Key Strengths?

Leading market position in the post-acute care industry.

  • Diversified service offerings across inpatient rehabilitation, home health, and hospice.
  • Extensive geographic footprint with a large network of facilities.
  • Strong brand reputation and relationships with payers.

What Are EHC's Weaknesses?

Exposure to regulatory changes and reimbursement pressures.

  • Labor shortages and rising labor costs in the healthcare industry.
  • Dependence on government funding and potential changes in healthcare policy.
  • Geographic concentration in certain regions, limiting growth opportunities.

What Could Drive EHC Stock Higher?

Continued expansion of inpatient rehabilitation facilities to meet growing demand.

  • Strategic acquisitions of home health and hospice agencies to increase market share.
  • Implementation of new telehealth and remote monitoring technologies to improve patient outcomes (expected Q4 2026).
  • Focus on value-based care initiatives to enhance reimbursement rates and attract more patients.
  • Demographic shifts with an aging population driving increased demand for post-acute care services.

What Are the Key Risks for EHC?

Insider selling — insiders were net sellers of roughly $29.3M recently.

  • Regulatory changes and reimbursement pressures impacting revenue and profitability.
  • Labor shortages and rising labor costs in the healthcare industry affecting operational efficiency.
  • Increased competition from other post-acute care providers eroding market share.
  • Cyberattacks and data breaches compromising patient information and disrupting operations.
  • Economic downturn potentially reducing patient volumes and impacting revenue.

What Are the Growth Opportunities for EHC?

  • Expansion of Inpatient Rehabilitation Facilities: Encompass Health can capitalize on the growing demand for inpatient rehabilitation services by strategically expanding its network of facilities. The market for inpatient rehabilitation is projected to reach $40 billion by 2028, driven by an aging population and increasing prevalence of chronic conditions. By adding new facilities in underserved markets and enhancing existing facilities with advanced technologies, Encompass Health can increase its market share and revenue. This expansion can be achieved through acquisitions, joint ventures, or greenfield developments, with a focus on high-growth regions.
  • Growth in Home Health and Hospice Services: The home health and hospice segment presents significant growth opportunities for Encompass Health. The market for home healthcare is expected to reach $300 billion by 2030, fueled by the increasing preference for home-based care and advancements in remote monitoring technologies. Encompass Health can expand its home health and hospice services by increasing its geographic coverage, enhancing its service offerings with specialized programs, and leveraging technology to improve patient outcomes and efficiency. Strategic acquisitions of smaller home health agencies can accelerate this growth.
  • Leveraging Technology and Telehealth: Encompass Health can enhance its service delivery and improve patient outcomes by leveraging technology and telehealth solutions. The telehealth market is projected to reach $175 billion by 2026, driven by the increasing adoption of remote monitoring, virtual consultations, and digital therapeutics. Encompass Health can invest in telehealth platforms to provide remote rehabilitation services, monitor patients' progress, and offer virtual consultations. This will improve access to care, reduce costs, and enhance patient satisfaction. The integration of AI-powered tools can further personalize treatment plans and optimize resource allocation.
  • Strategic Partnerships and Collaborations: Encompass Health can strengthen its market position and expand its service offerings by forming strategic partnerships and collaborations with other healthcare providers, payers, and technology companies. Collaborating with hospitals and physician groups can create referral networks and ensure a steady stream of patients. Partnering with payers can develop value-based care models and improve reimbursement rates. Collaborating with technology companies can integrate innovative solutions into its service delivery. These partnerships can enhance Encompass Health's competitive advantage and drive revenue growth.
  • Focus on Value-Based Care: Encompass Health can capitalize on the shift towards value-based care by demonstrating its ability to deliver high-quality, cost-effective post-acute care. Value-based care models reward providers for achieving positive patient outcomes and reducing healthcare costs. Encompass Health can invest in data analytics and quality improvement initiatives to track patient outcomes, identify areas for improvement, and demonstrate its value to payers. By participating in value-based care programs, Encompass Health can increase its reimbursement rates and attract more patients.

What Are EHC's Competitive Advantages?

  • Established brand reputation and market leadership in the post-acute care industry.
  • Extensive network of hospitals, home health locations, and hospice locations across multiple states.
  • Specialized expertise in providing comprehensive rehabilitation and home healthcare services.
  • Strong relationships with payers, including Medicare, Medicaid, and commercial insurance companies.

What Does EHC Do?

Encompass Health Corporation, founded in 1983 and headquartered in Birmingham, Alabama, has evolved into a prominent provider of facility-based and home-based post-acute healthcare services across the United States. Originally known as HealthSouth Corporation, the company rebranded in January 2018 to reflect its expanded focus. Encompass Health operates through two primary segments: Inpatient Rehabilitation and Home Health & Hospice. The Inpatient Rehabilitation segment delivers specialized rehabilitative treatment to patients recovering from conditions such as stroke, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. These services are offered on both an inpatient and outpatient basis. The Home Health & Hospice segment provides a range of home health services, including skilled nursing, medical social work, and home health aide services, along with physical, occupational, and speech therapy, primarily in the Southeast and Texas. This segment also offers in-home hospice services to terminally ill patients and their families. As of June 1, 2022, Encompass Health operated 149 hospitals, 252 home health locations, and 99 hospice locations across 42 states and Puerto Rico, demonstrating its extensive national footprint and commitment to delivering comprehensive post-acute care.

What Products and Services Does EHC Offer?

  • Operates inpatient rehabilitation facilities providing specialized treatment for patients recovering from serious injuries and illnesses.
  • Offers home health services, including skilled nursing, therapy, and medical social work, in patients' homes.
  • Provides hospice care for terminally ill patients and their families, focusing on comfort and support.
  • Manages a network of hospitals, home health locations, and hospice locations across multiple states.
  • Delivers rehabilitative treatment on an outpatient basis.
  • Offers specialized programs for conditions such as stroke, neurological disorders, and orthopedic injuries.
  • Coordinates care with physicians, hospitals, and other healthcare providers to ensure seamless transitions for patients.

How Does EHC Make Money?

  • Generates revenue through facility-based inpatient and outpatient rehabilitation services.
  • Earns revenue from home health services, including skilled nursing and therapy.
  • Receives payments for hospice care services provided to terminally ill patients.
  • Contracts with Medicare, Medicaid, commercial insurance companies, and private payers for reimbursement.

What Industry Does EHC Operate In?

Encompass Health operates within the expanding post-acute care industry, driven by an aging population and increasing prevalence of chronic diseases. The market is characterized by a growing demand for rehabilitation and home healthcare services. The competitive landscape includes national and regional providers, as well as smaller, independent operators. Encompass Health's scale, geographic reach, and comprehensive service offerings position it as a leading player in this fragmented market. Competitors include ENSG: The Ensign Group, Inc., which also operates in the skilled nursing and rehabilitation space.

Who Are EHC's Key Customers?

  • Patients recovering from stroke, neurological disorders, cardiac conditions, and other serious illnesses or injuries.
  • Individuals requiring skilled nursing, therapy, or other healthcare services in their homes.
  • Terminally ill patients and their families seeking hospice care and support.
  • Hospitals and physician groups that refer patients to Encompass Health for post-acute care.
Model self-rating on this text: 72% (not a measure of the evidence) Updated: May 9, 2026

Research confidence

High 100/100

Broad, current evidence sits behind this analysis.

  • Scored on 100% of our measures
  • Price is current
  • Latest filing 35 days ago
  • Covered by analysts

Why 89?

Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.

What is helping

  • +0.78 Gross profit per dollar of assets (Business Quality)
  • +0.60 Financial-health checklist (Financial Strength)
  • +0.51 Return on equity (Business Quality)

What is holding it back

  • -0.60 Debt to equity (Financial Strength)
  • -0.18 Net debt vs earnings (Financial Strength)
  • -0.14 Short-term liquidity (Financial Strength)

Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 88
2026-08-26 88
2026-08-29 89
2026-09-01 87
2026-09-04 88
2026-09-07 88
2026-09-10 88

What changed?

The score has stayed at 88.

What moved it up or down:

  • -12 Valuation
  • +9 Momentum
  • +2 Growth Durability

Over the same 18 days the stock moved +1.0%.

Net selling

Insider Activity

Over the past six months, Encompass Health Corporation insiders filed 44 SEC Form 4 transactions — 11 sales and 33 purchases. On net that is roughly 223K shares disposed (about $29.3M), a signal worth weighing alongside the fundamentals.

8/8 beats

Earnings Track Record

Encompass Health Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.6% above estimates on average.

F-Score 8/9

Financial Health

Encompass Health Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.48 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 25%

Key Financial Metrics

Return on equity for Encompass Health Corporation stands at 25.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.3%, showing how much profit it generates from its asset base. EHC trades at a trailing price-to-earnings ratio of 16.46, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.1%, the inverse of the P/E and a quick read on earnings relative to price.

Encompass Health Corporation (EHC) Valuation Context

Valued at $12.0B, EHC is classified as a large-cap stock. Analyst price targets span from $144.00 to $155.00, with a consensus of $150.25. At the current price of $121.04, that implies approximately 24% upside potential. Relative to its peer group, EHC's quantitative score of 89/100 is above the peer average of 79/100.

EHC Revenue & Earnings Trend

In Q2 FY2026, EHC generated $1.60B in top-line revenue, marking a sequential increase of 0.7%. The company recorded net income of $153.9M, with diluted EPS of $1.54. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, EHC averaged $1.54 in diluted EPS.

Company Profile

Encompass Health Corporation operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Birmingham, US. The company is led by CEO Mark J. Tarr. EHC has traded publicly since 1986.

EHC Financials

Fundamental Snapshot

Revenue Growth (FY)
+10.5%
Net Income Growth (FY)
+24.2%
EPS Growth (FY)
+24.1%
Free Cash Flow Growth (FY)
+21.9%
P/E (TTM)
16.46
Return on Equity (TTM)
+25.3%
Current Ratio
1.2
EV/EBITDA (TTM)
8.7

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Leading market position in the post-acute care industry.
  • Diversified service offerings across inpatient rehabilitation, home health, and hospice.
  • Extensive geographic footprint with a large network of facilities.
  • Strong brand reputation and relationships with payers.

Bear Case

  • Exposure to regulatory changes and reimbursement pressures.
  • Labor shortages and rising labor costs in the healthcare industry.
  • Dependence on government funding and potential changes in healthcare policy.
  • Geographic concentration in certain regions, limiting growth opportunities.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 FY2026 $1.60B $154M $1.54
Q1 FY2026 $1.59B $195M $1.93
Q4 FY2025 $1.54B $146M $1.43
Q3 FY2025 $1.48B $127M $1.24

Q2 FY2026 · filed 7 Aug 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

EHC Latest News

EHC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EHC.

Price Targets

Low
$144.00
Consensus
$150.25
High
$155.00

Median: $151.00 (+24.1% from current price)

Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice

EHC MoonshotScore

89/100

What does this score mean?

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. EHC scores 89/100 (Grade A+): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Leadership: Mark J. Tarr

Chief Executive Officer

Mark J. Tarr serves as the Chief Executive Officer of Encompass Health Corporation, bringing extensive experience in healthcare leadership. Prior to his role at Encompass Health, Tarr held various executive positions within the healthcare industry, including leadership roles at Gentiva Health Services and United Surgical Partners International. He holds a bachelor's degree in business administration from Indiana University.

Track Record: Since assuming the role of CEO, Mark J. Tarr has overseen Encompass Health's strategic expansion and diversification of its service offerings. He has led the company through significant milestones, including the rebranding from HealthSouth Corporation to Encompass Health Corporation in 2018. Under his leadership, Encompass Health has strengthened its market position and enhanced its focus on delivering high-quality, cost-effective post-acute care.

Common Questions About EHC (Healthcare)

What does the AI Score mean for EHC?

EHC holds an AI Score of 89/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States.

Is EHC a good stock?

Stock Expert AI does not rate EHC buy, sell or hold. Encompass Health Corporation carries a MoonshotScore of 89/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

What do analysts say about EHC stock?

Analyst consensus on Encompass Health Corporation (EHC) is generally positive, reflecting the company's strong market position and growth prospects in the post-acute care industry. Key valuation metrics, such as the P/E ratio of 16.46, suggest a reasonable valuation relative to earnings.

What are the key factors to evaluate for EHC?

Encompass Health Corporation (EHC) holds a MoonshotScore of 89/100 (high). P/E: 16.46x vs the S&P 500's ~20-25x. Analysts target $150.25 (+24%). Not financial advice.

How frequently does EHC data refresh on this page?

EHC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven EHC's recent stock price performance?

Encompass Health Corporation (EHC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in the post-acute care industry. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider EHC overvalued or undervalued right now?

Encompass Health Corporation (EHC) trades at 16.46x earnings. Analysts target $150.25 (+24%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of EHC?

Yes, most major brokerages offer fractional shares of Encompass Health Corporation (EHC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track EHC's earnings and financial reports?

Encompass Health Corporation (EHC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for EHC earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated MoonshotScore as of
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Financial data is as of the latest available reporting period.
  • Analyst opinions and ratings are subject to change without notice.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover